An ex-Pfizer drug that one of Roivant’s subsidiaries is developing surpassed expectations in a study of people with a non-infectious form of uveitis, the company said.

In its second-quarter update earlier this month, eye drug developer Clearside Biomedical indicated it was looking to out-license its lead drug, Xipere, which is currently under FDA review. But those plans may be put on hold after the company on Thursday disclosed the FDA has asked for more data on the drug’s marketing application.